Reni Benjamin has given his Buy rating due to a combination of factors that highlight Iovance Biotherapeutics’ promising investment potential. The company has demonstrated strong performance ...
Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE ...
Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company ...
Whenever you make any purchase through links on this website, eFestivals may earn a commission. You will never be charged more if you purchase via our links, but you will be directly helping to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback